Evidence map›Paper›PMID 26434537›Full record

ReviewAdvanced drug delivery reviews2015

Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy.

Harutaka Mekaru, Jie Lu, Fuyuhiko Tamanoi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 256 citations in OpenAlex.

  1. Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Harutaka MekaruDept. of Microbio., Immunol. & Molec. Genet. Jonsson Comprehensive Cancer Center Molecular Biology Institute , University of California, Los Angeles, CA, United States.
Jie LuDept. of Microbio., Immunol. & Molec. Genet. Jonsson Comprehensive Cancer Center Molecular Biology Institute , University of California, Los Angeles, CA, United States.
Fuyuhiko TamanoiDept. of Microbio., Immunol. & Molec. Genet. Jonsson Comprehensive Cancer Center Molecular Biology Institute , University of California, Los Angeles, CA, United States. Electronic address: fuyut@microbio.ucla.edu.
University of California, Los Angeles · US

Funding

Nanovalve Platform: Targeted, Controlled, Release of Anticancer DrugsR01CA133697 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS, STODDART, JAMES FRASER · 2010 to 2014
$2.1M
NCI NIH HHS CA133697NCI NIH HHS R01 CA133697
6 · The paper itself

Abstract

Nanoparticles that respond to internal and external stimuli to carry out controlled release of anticancer drugs have been developed. In this review, we focus on the development of mesoporous silica based nanoparticles, as this type of materials provides a relatively stable material that is amenable to various chemical modifications. We first provide an overview of various designs employed to construct MSN-based controlled release systems. These systems respond to internal stimuli such as pH, redox state and the presence of biomolecules as well as to external stimuli such as light and magnetic field. They are at a different stage of development; depending on the system, their operation has been demonstrated in aqueous solution, in cancer cells or in animal models. Efforts to develop MSNs with multi-functionality will be discussed. Safety and biodegradation of MSNs, issues that need to be overcome for clinical development of MSNs, will be discussed. Advances in the synthesis of mechanized theranostic nanoparticles open up the possibility to start envisioning future needs for medical equipment.

Indexed as

Drug Delivery SystemsNanoparticlesSilicon DioxideAnimalsAntineoplastic AgentsDelayed-Action PreparationsHumansNeoplasmsPorosityAntineoplastic AgentsDelayed-Action PreparationsSilicon DioxideControlled releaseMesoporous silica nanoparticlesNanoimpellerNanovalveOscillating magnetic fieldTargetingTwo photon excitation

Identifiers

PMID26434537
PMCPMC4663124
OpenAlexW1801425213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.